Median survival in patients with polycythemia vera (PV), which is 1.5-3 years in the absence of therapy.
The median survival has been extended to approximately 14 years overall, and to 24 years for patients younger than 60 years of age - this is because the availability of new therapeutic tools.
The relationship of the disease to other myeloproliferative disorders is evidenced by the tendency in some patients to transform after a period to acute leukaemia - in 10 to 20% of patients - or to myelofibrosis - in one third of all patients.
Reference:
Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.